Assessment of NAC efficacy for reducing of craving in patients with methamphetamine dependency

Phase 3

• Conditions: Methamphetamine Dependency.; Mental and behavioural disorders due to psychoactive substance use

• Registration Number: IRCT201205317841N2
• Lead Sponsor: Isfahan University of Medical Sciences, Behavioral Sciences Research Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1) men and women aged 18–65 years old; 2) informed acceptance to comply with study procedures. Exclusion criteria: 1) sever medical illness that would impair the ability to participate safely in the study; 2) a current neurological or axis I psychiatric disorders not due to substance abuse (e.g., schizophrenia, dementia) that would impair ability to participate safely in the study; 3) current pregnancy or nursing in women; 4) current serious suicidal intention or plan; 5) more than 3 times elevation of AST and ALT at screening; 6) past medical history of asthma or seizures; 7) Subjects who had recently used medications (<14 days) felt to be hazardous if taken with NAC (e.g. carbamazepine, nitroglycerin); and 8) subjects who met DSM-IV criteria for opiates dependence. Also in following conditions the patient will be out of study: 1) incidence of seizure or sever medical illness that would impair ability to participate safely in the study; 2) non compliance or not willing for continuing the study; 3) sever and unbearable drug side effect even after reducing the dose.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Methamphetamine Craving. Timepoint: At screening and every 2 weeks up to 6 weeks. Method of measurement: Cocaine Craving Questionnaire-Brief (CCQ-Brief).